{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T00:38:29Z","timestamp":1793752709558,"version":"4.6.1"},"reference-count":33,"publisher":"American Society of Hematology","issue":"23","license":[{"start":{"date-parts":[[2022,3,26]],"date-time":"2022-03-26T00:00:00Z","timestamp":1648252800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,6,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Few studies have described chimeric antigen receptor (CAR) T-cell therapy for patients with B-cell acute lymphoblastic leukemia (B-ALL) with central nervous system leukemia (CNSL) because of concerns regarding poor response and treatment-related neurotoxicity. Our study included 48 patients with relapsed\/refractory B-ALL with CNSL to evaluate the efficacy and safety of CD19-specific CAR T cell\u2013based therapy. The infusion resulted in an overall response rate of 87.5% (95% confidence interval [CI], 75.3-94.1) in bone marrow (BM) disease and remission rate of 85.4% (95% CI, 72.8-92.8) in CNSL. With a median follow-up of 11.5 months (range, 1.3-33.3), the median event-free survival was 8.7 months (95% CI, 3.7-18.8), and the median overall survival was 16.0 months (95% CI, 13.5-20.1). The cumulative incidences of relapse in BM and CNS diseases were 31.1% and 11.3%, respectively, at 12 months (P = .040). The treatment was generally well tolerated, with 9 patients (18.8%) experiencing grade \u22653 cytokine release syndrome. Grade 3 to 4 neurotoxic events, which developed in 11 patients (22.9%), were associated with a higher preinfusion disease burden in CNS and were effectively controlled under intensive management. Our results suggest that CD19-specific CAR T cell\u2013based therapy can induce similar high response rates in both BM and CNS diseases. The duration of remission in CNSL was longer than that in BM disease. CD19 CAR T-cell therapy may provide a potential treatment option for previously excluded patients with CNSL, with manageable neurotoxicity. The clinical trials were registered at www.clinicaltrials.gov as #NCT02782351 and www.chictr.org.cn as #ChiCTR-OPN-16008526.<\/jats:p>","DOI":"10.1182\/blood.2021013733","type":"journal-article","created":{"date-parts":[[2022,3,26]],"date-time":"2022-03-26T16:08:51Z","timestamp":1648310931000},"page":"3376-3386","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":102,"title":["Efficacy and safety of CD19-specific CAR T cell\u2013based therapy in B-cell acute lymphoblastic leukemia patients with CNSL"],"prefix":"10.1182","volume":"139","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4431-3060","authenticated-orcid":false,"given":"Yuekun","family":"Qi","sequence":"first","affiliation":[{"name":"1Blood Diseases Institute, Xuzhou Medical University, Xuzhou, China;"},{"name":"2Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingfeng","family":"Zhao","sequence":"additional","affiliation":[{"name":"3Department of Hematology, Tianjin First Central Hospital, Tianjin, China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongxian","family":"Hu","sequence":"additional","affiliation":[{"name":"4Bone Marrow Transplantation Center, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Wang","sequence":"additional","affiliation":[{"name":"1Blood Diseases Institute, Xuzhou Medical University, Xuzhou, China;"},{"name":"2Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Li","sequence":"additional","affiliation":[{"name":"5Department of Hematology, Tongji Hospital of Tongji University, Shanghai, China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3767-9283","authenticated-orcid":false,"given":"Jiang","family":"Cao","sequence":"additional","affiliation":[{"name":"1Blood Diseases Institute, Xuzhou Medical University, Xuzhou, China;"},{"name":"2Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Shi","sequence":"additional","affiliation":[{"name":"6Cancer Institute, Xuzhou Medical University, Xuzhou, China;"},{"name":"7Center of Clinical Oncology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaqi","family":"Tan","sequence":"additional","affiliation":[{"name":"8Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Zhang","sequence":"additional","affiliation":[{"name":"3Department of Hematology, Tianjin First Central Hospital, Tianjin, China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Xiao","sequence":"additional","affiliation":[{"name":"3Department of Hematology, Tianjin First Central Hospital, Tianjin, China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jieyun","family":"Xia","sequence":"additional","affiliation":[{"name":"1Blood Diseases Institute, Xuzhou Medical University, Xuzhou, China;"},{"name":"2Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sha","family":"Ma","sequence":"additional","affiliation":[{"name":"1Blood Diseases Institute, Xuzhou Medical University, Xuzhou, China;"},{"name":"2Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0456-0940","authenticated-orcid":false,"given":"Jianlin","family":"Qiao","sequence":"additional","affiliation":[{"name":"1Blood Diseases Institute, Xuzhou Medical University, Xuzhou, China;"},{"name":"2Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiling","family":"Yan","sequence":"additional","affiliation":[{"name":"1Blood Diseases Institute, Xuzhou Medical University, Xuzhou, China;"},{"name":"2Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hujun","family":"Li","sequence":"additional","affiliation":[{"name":"1Blood Diseases Institute, Xuzhou Medical University, Xuzhou, China;"},{"name":"2Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Pan","sequence":"additional","affiliation":[{"name":"1Blood Diseases Institute, Xuzhou Medical University, Xuzhou, China;"},{"name":"2Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1170-7074","authenticated-orcid":false,"given":"Wei","family":"Sang","sequence":"additional","affiliation":[{"name":"1Blood Diseases Institute, Xuzhou Medical University, Xuzhou, China;"},{"name":"2Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Depeng","family":"Li","sequence":"additional","affiliation":[{"name":"1Blood Diseases Institute, Xuzhou Medical University, Xuzhou, China;"},{"name":"2Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenyu","family":"Li","sequence":"additional","affiliation":[{"name":"1Blood Diseases Institute, Xuzhou Medical University, Xuzhou, China;"},{"name":"2Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianfeng","family":"Zhou","sequence":"additional","affiliation":[{"name":"8Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"He","family":"Huang","sequence":"additional","affiliation":[{"name":"4Bone Marrow Transplantation Center, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aibin","family":"Liang","sequence":"additional","affiliation":[{"name":"5Department of Hematology, Tongji Hospital of Tongji University, Shanghai, China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junnian","family":"Zheng","sequence":"additional","affiliation":[{"name":"6Cancer Institute, Xuzhou Medical University, Xuzhou, China;"},{"name":"7Center of Clinical Oncology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1375-1084","authenticated-orcid":false,"given":"Kailin","family":"Xu","sequence":"additional","affiliation":[{"name":"1Blood Diseases Institute, Xuzhou Medical University, Xuzhou, China;"},{"name":"2Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"2","key":"2022060915220540000_B1","first-page":"106","article-title":"Recent advances in adult acute lymphoblastic leukemia","volume":"14","author":"Richard-Carpentier","year":"2019","journal-title":"Curr Hematol Malig Rep."},{"issue":"11","key":"2022060915220540000_B2","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/s41408-020-00383-2","article-title":"Updated risk-oriented strategy for acute lymphoblastic leukemia in adult patients 18-65 years: NILG ALL 10\/07","volume":"10","author":"Bassan","year":"2020","journal-title":"Blood Cancer J."},{"issue":"9","key":"2022060915220540000_B3","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.3390\/jcm10091926","article-title":"Advances in the diagnosis and treatment of pediatric acute lymphoblastic leukemia","volume":"10","author":"Inaba","year":"2021","journal-title":"J Clin Med."},{"issue":"5","key":"2022060915220540000_B4","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia","volume":"378","author":"Park","year":"2018","journal-title":"N Engl J Med."},{"issue":"5","key":"2022060915220540000_B5","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med."},{"issue":"15","key":"2022060915220540000_B6","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1182\/blood-2018-11-883710","article-title":"Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy","volume":"133","author":"Hay","year":"2019","journal-title":"Blood."},{"issue":"1","key":"2022060915220540000_B7","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1182\/blood.2020009098","article-title":"KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed\/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results","volume":"138","author":"Shah","year":"2021","journal-title":"Blood."},{"issue":"1","key":"2022060915220540000_B8","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s13045-016-0299-5","article-title":"Predominant cerebral cytokine release syndrome in CD19-directed chimeric antigen receptor-modified T cell therapy","volume":"9","author":"Hu","year":"2016","journal-title":"J Hematol Oncol."},{"issue":"1","key":"2022060915220540000_B9","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/cpt.1674","article-title":"CAR T-cell therapy in hematologic malignancies: a voyage in progress","volume":"107","author":"Holstein","year":"2020","journal-title":"Clin Pharmacol Ther."},{"issue":"8","key":"2022060915220540000_B10","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1038\/s41375-019-0437-5","article-title":"Anti-CD19 CAR-T as a feasible and safe treatment against central nervous system leukemia after intrathecal chemotherapy in adults with relapsed or refractory B-ALL","volume":"33","author":"He","year":"2019","journal-title":"Leukemia."},{"issue":"5","key":"2022060915220540000_B11","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1007\/s11899-018-0470-x","article-title":"CAR-T cell therapy for acute lymphoblastic leukemia: transforming the treatment of relapsed and refractory disease","volume":"13","author":"Pehlivan","year":"2018","journal-title":"Curr Hematol Malig Rep."},{"issue":"9967","key":"2022060915220540000_B12","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","article-title":"T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial","volume":"385","author":"Lee","year":"2015","journal-title":"Lancet."},{"issue":"8","key":"2022060915220540000_B13","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJMc1704610","article-title":"Anti-CD19 CAR T cells in CNS diffuse large-B-cell lymphoma","volume":"377","author":"Abramson","year":"2017","journal-title":"N Engl J Med."},{"issue":"12","key":"2022060915220540000_B14","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1002\/ajh.25274","article-title":"Locally produced CD19 CAR T cells leading to clinical remissions in medullary and extramedullary relapsed acute lymphoblastic leukemia","volume":"93","author":"Jacoby","year":"2018","journal-title":"Am J Hematol."},{"issue":"10","key":"2022060915220540000_B15","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1182\/bloodadvances.2020001466","article-title":"Efficacy and safety of anti-CD19 CAR T-cell therapy in 110 patients with B-cell acute lymphoblastic leukemia with high-risk features","volume":"4","author":"Zhang","year":"2020","journal-title":"Blood Adv."},{"issue":"20","key":"2022060915220540000_B16","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood."},{"issue":"10","key":"2022060915220540000_B17","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.6004\/jnccn.2015.0153","article-title":"Acute lymphoblastic leukemia, version 2.2015","volume":"13","author":"Alvarnas","year":"2015","journal-title":"J Natl Compr Canc Netw."},{"issue":"7","key":"2022060915220540000_B18","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1002\/ajh.25108","article-title":"Potent anti-leukemia activities of humanized CD19-targeted chimeric antigen receptor T (CAR-T) cells in patients with relapsed\/refractory acute lymphoblastic leukemia","volume":"93","author":"Cao","year":"2018","journal-title":"Am J Hematol."},{"issue":"1","key":"2022060915220540000_B19","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1182\/blood.2019000017","article-title":"Efficacy and safety of CAR19\/22 T-cell cocktail therapy in patients with refractory\/relapsed B-cell malignancies","volume":"135","author":"Wang","year":"2020","journal-title":"Blood."},{"issue":"4","key":"2022060915220540000_B20","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant."},{"issue":"26","key":"2022060915220540000_B21","doi-asserted-by":"crossref","first-page":"3321","DOI":"10.1182\/blood-2016-04-703751","article-title":"Toxicities of chimeric antigen receptor T cells: recognition and management","volume":"127","author":"Brudno","year":"2016","journal-title":"Blood."},{"issue":"4","key":"2022060915220540000_B22","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/sj.bmt.1705727","article-title":"Competing risk analysis using R: an easy guide for clinicians","volume":"40","author":"Scrucca","year":"2007","journal-title":"Bone Marrow Transplant."},{"issue":"35","key":"2022060915220540000_B23","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1200\/JCO.19.01692","article-title":"Improved CNS control of childhood acute lymphoblastic leukemia without cranial irradiation: St Jude Total Therapy Study 16","volume":"37","author":"Jeha","year":"2019","journal-title":"J Clin Oncol."},{"issue":"11","key":"2022060915220540000_B24","doi-asserted-by":"crossref","first-page":"e280","DOI":"10.1016\/j.bbmt.2020.07.036","article-title":"Chimeric antigen receptor T cell therapy in patients with multiply relapsed or refractory extramedullary leukemia","volume":"26","author":"Rubinstein","year":"2020","journal-title":"Biol Blood Marrow Transplant."},{"issue":"4","key":"2022060915220540000_B25","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1182\/blood.2020010438","article-title":"Prognostic factors for CNS control in children with acute lymphoblastic leukemia treated without cranial irradiation","volume":"138","author":"Tang","year":"2021","journal-title":"Blood."},{"issue":"4","key":"2022060915220540000_B26","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.3390\/ijms22042150","article-title":"A review of clinical outcomes of CAR T-cell therapies for B-acute lymphoblastic leukemia","volume":"22","author":"Martino","year":"2021","journal-title":"Int J Mol Sci."},{"issue":"11","key":"2022060915220540000_B27","doi-asserted-by":"crossref","first-page":"e816","DOI":"10.1016\/S2352-3026(20)30277-5","article-title":"Anti-CD19 chimeric antigen receptor T-cell therapy in acute lymphocytic leukaemia: a systematic review and meta-analysis","volume":"7","author":"Anagnostou","year":"2020","journal-title":"Lancet Haematol."},{"issue":"8","key":"2022060915220540000_B28","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1158\/2159-8290.CD-17-1319","article-title":"Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia","volume":"8","author":"Santomasso","year":"2018","journal-title":"Cancer Discov."},{"key":"2022060915220540000_B29","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.blre.2018.11.002","article-title":"Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management","volume":"34","author":"Brudno","year":"2019","journal-title":"Blood Rev."},{"issue":"1","key":"2022060915220540000_B30","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy \u2013 assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat Rev Clin Oncol."},{"key":"2022060915220540000_B31","doi-asserted-by":"crossref","first-page":"3019","DOI":"10.1200\/JCO.2017.35.15_suppl.3019","article-title":"Biomarkers associated with neurotoxicity in adult patients with relapsed or refractory B-ALL (R\/R B-ALL) treated with CD19 CAR T cells [abstract]","volume":"35","author":"Santomasso","year":"2017","journal-title":"J Clin Oncol."},{"issue":"12","key":"2022060915220540000_B32","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1158\/2159-8290.CD-17-0698","article-title":"Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells","volume":"7","author":"Gust","year":"2017","journal-title":"Cancer Discov."},{"issue":"12","key":"2022060915220540000_B33","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1007\/s40263-018-0582-9","article-title":"Neurotoxicity associated with CD19-targeted CAR-T cell therapies","volume":"32","author":"Gust","year":"2018","journal-title":"CNS Drugs."}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/139\/23\/3376\/1901187\/bloodbld2021013733.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/139\/23\/3376\/1901187\/bloodbld2021013733.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,9]],"date-time":"2022-06-09T11:22:32Z","timestamp":1654773752000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/139\/23\/3376\/484499\/Efficacy-and-safety-of-CD19-specific-CAR-T-cell"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,9]]},"references-count":33,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2022,6,9]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2021013733","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,9]]}}}